A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples

• Conditions: Carcinoma, Non-Small-Cell Lung

• Registration Number: NCT01382992
• Lead Sponsor: Peking Union Medical College Hospital

Brief Summary

EGFR mutations plays an essential role in EGFR-TKIs treatment. However, for some patients, tissue samples are not available. The purpose of this study is to determine whether blood sample is feasible for EGFR mutation detection.For late stage NSCLC, we hypothesis plasma sample is an alternative for detecting EGFR mutations.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-06
• Status Verified: 2011-06
• Study First Submitted: 2011-06-24
• Study First Submitted QC: 2011-06-24
• Last Update Submitted: 2011-06-24
• Study First Posted: 2011-06-27
• Last Update Posted: 2011-06-27

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Non-small cell lung cancer
• Available plasma and pathologically confirmed tissue slices(pre-chemo and pre-radio therapy)
• Informed Consent

Exclusion Criteria

• N/A

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine the consistence of EGFR mutation status in paired tissue and plasma samples	3 months

Secondary Outcome Measures

Name	Time	Method
To determine the EGFR mutation status in Chinese NSCLC	3month

Trial Locations

Locations (1)

Peking Union Medical College Hospital; 🇨🇳 Beijing, China